First Patient Enrolled in Revita® Wound Care Study


We’re excited to announce the commencement of our second level 1 clinical study for Revita!

This level 1 randomized controlled trial will assess the safety and efficacy of Revita as a wound covering for diabetic foot ulcers (DFUs). Diabetes impacts 30 million people across the United States, and as many as 25% of diabetic patients will develop a DFU within their lifetime.1-2 Without proper treatment, DFUs commonly result in amputation, leaving the patient with a 50% chance of survival. 3-4

As the first placental membrane allograft to capture the complete intact membrane in a shelf-stable format, Revita is uniquely capable of addressing DFUs. Since the product was launched, Revita has shown excellent effectiveness as a wound covering for a broad range of wound types including DFUs. This study will build on that experience and demonstrate broader, clinically validated outcomes.

We are thrilled to have this trial underway and are continuing to invest in high quality outcomes data for the complete portfolio of StimLabs products.

More information on this study can be found press release.

MKTG 19- 004 Rev 01

1. American Diabetes Association. Statistics About Diabetes. 2018 Mar.2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA2005;293:217–228pmid:1564454.3. Alexiadou, Management of Diabetic Foot Ulcers. 2012 Apr 20.4. Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286–287pmid:18154621

First Patient Enrolled in Revita® Spine Study

We’re excited to announce our first level 1 clinical study for Revita full thickness placental allograft!


This clinical trial will assess the safety and efficacy of Revita placement following lumbar microdiscectomy procedures. Common complications following microdiscectomy procedures include scar tissue formation and reherniation, which are known to cause back and leg pain. Patients with extensive scar tissue are 3.2 times more likely to experience recurrent radicular pain than those with less extensive scarring1.

The use of a barrier membrane, such as Revita, is expected to reduce the rate of occurrence for these types of complications and improve functional outcomes following surgery. The first patient has been enrolled in a 182-patient multi-center randomized controlled single-blinded (patient) trial evaluating the use of Revita as a barrier membrane to reduce these types of complications and improve functional outcomes. More information on this study can be found in the press release.

We are thrilled to have this trial underway, and we are continuing to invest in robust clinical validation of both Revita and Ascent through several case series and large randomized controlled trials.

MKTG 18-020 Rev 01

1. Ross et al,. Association between peridural scar and recurrent radicular pain after lumbar discectomy: magnetic resonance evaluation. ADCON-L European Study Group. AJNR Am J Neuroradiol, January 1998, 19:183–186

Redefining Regenerative Medicine

The healing cascade is a complex and dynamic series of phases that has been studied in depth and characterized into three general phases: inflammation, proliferation, and maturation. During these stages, signaling proteins and local cells work to repair the injured tissue back to its original form. The problem? The healing process, like many functions of the body, is not perfect. Scars, for example, are a visual representation of how a wound is unable to fully return to its original form and function. Even when a scar appears to have dissipated, the ‘new’ tissue formed is dissimilar and more vulnerable than the original tissue.

What’s the point?

In an ideal world, tissue would be restored perfectly back to its inherent function and structure. This notion of optimized healing is the foundation for StimLabs' conception. StimLabs believes in optimizing the healing cascade by advancing research and development within regenerative medicine.

Back up. What is regenerative medicine?

Read More

Why create a blog?

We want to share our perspective and establish an open line of communication with clinicians, scientists, patients and more. We’ll be using this blog as a forum for a few different topics.

1. Corporate Updates

Being new and different requires clarity. As our first two products have redefined what’s possible with placental tissue, we’ve found the need to have a forum for company updates.

2. Scientific Clarity

The new world of regenerative medicine is largely unexplored. As a result, there is a lot of conflicting information about the science behind products. Our Product Development team has spent their careers researching and developing new technologies, and we want to share some of the information they’ve gathered.

3. Product Updates

We move quickly with new initiatives. Within a year of founding StimLabs, we brought Revita to market, and just a few months later, we brought Ascent to market. As you’ll learn in our next post, we’re plotting a course for even more ambitious products, and our current offerings are just the beginning.

We’re excited about the future, and are looking forward to an open dialogue with the scientific and clinical communities about products that will have a lasting impact on patient care.

MKTG 18-008 Rev 01